Last reviewed · How we verify

Dexamethasone and ondasetron

Instituto Materno Infantil Prof. Fernando Figueira · Phase 3 active Small molecule

Dexamethasone suppresses inflammation and immune responses via glucocorticoid receptor activation, while ondansetron blocks serotonin 5-HT3 receptors to prevent nausea and vomiting.

Dexamethasone suppresses inflammation and immune responses via glucocorticoid receptor activation, while ondansetron blocks serotonin 5-HT3 receptors to prevent nausea and vomiting. Used for Prevention and management of nausea and vomiting in pediatric patients (likely postoperative or chemotherapy-related), Inflammatory conditions requiring corticosteroid support with antiemetic coverage.

At a glance

Generic nameDexamethasone and ondasetron
Also known asDecadron and nausedron
SponsorInstituto Materno Infantil Prof. Fernando Figueira
Drug classCorticosteroid + 5-HT3 antagonist combination
TargetGlucocorticoid receptor (dexamethasone); 5-HT3 receptor (ondansetron)
ModalitySmall molecule
Therapeutic areaSupportive Care / Antiemetic
PhasePhase 3

Mechanism of action

Dexamethasone is a potent corticosteroid that reduces inflammation, suppresses immune cell activity, and decreases cytokine production. Ondansetron is a selective 5-HT3 antagonist that blocks serotonin signaling in the chemoreceptor trigger zone and gastrointestinal tract, preventing chemotherapy-induced and postoperative nausea and vomiting. This combination is used to manage nausea, vomiting, and inflammatory complications in clinical settings.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: